ZIVO Bioscience: Coccidiosis Treatment Licensing Opportunities
Monday, Dec 23, 2024 8:11 am ET
ZIVO Bioscience, Inc. (OTCQB: ZIVO) has made significant strides in its mission to develop and commercialize a novel, non-antibiotic treatment for coccidiosis in broiler chickens. The company's recent announcements highlight its progress in licensing opportunities, regulatory clarity, and potential market impact.
ZIVO's innovative product candidate, derived from proprietary algal cultures, has demonstrated remarkable efficacy in real-world conditions. The company's 42-day validation study, conducted in collaboration with the University of Delaware, confirmed the product's ability to maintain broiler health against coccidiosis, outperforming market-leading products and offering a non-antibiotic, non-chemical alternative. These results have positioned ZIVO to pursue strategic partnerships with global animal health companies.

In a recent development, ZIVO received a letter from the U.S. Department of Agriculture's (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the company's novel immune-modulating biologic. This regulatory clarity enables ZIVO to advance discussions with the CVB on the final product development plan, regulatory strategy, and data requirements for licensure. The CVB's jurisdictional announcement removes regulatory ambiguity and provides a path for a comprehensive review, expediting ZIVO's approval path.
ZIVO's product candidate represents a substantial market opportunity, given the global poultry industry's annual spend of over $1.5 billion on coccidiosis control. Assuming a conservative royalty rate of 5% on annual sales of $500 million, ZIVO could potentially earn $25 million in royalties annually, contributing significantly to its overall revenue growth.
The company's strategic focus on licensing opportunities, regulatory clarity, and market potential positions ZIVO Bioscience as an attractive investment prospect in the animal health sector. As the company continues to advance its product pipeline and expand its market reach, investors should closely monitor ZIVO's progress and consider the potential long-term value of its innovative coccidiosis treatment.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
haha
lol
I've always been a strong advocate for diversifying my investments, and early in 2023, I decided to take the plunge into
cryptocurrency with a €3,000 investment in Bitcoin. The experience was a rollercoaster-watching the market's ups and downs was both exhilarating and nerve-wracking. By the time Bitcoin peaked in 2024, my investment had grown to nearly €20,000!
I made a strategic decision to withdraw a portion to secure my retirement, leaving a smaller share to ride the wave of potential future growth. While this journey has been one of the most rewarding financial decisions I've ever made, it wasn't without its challenges.
Thankfully, I had the guidance of a seasoned financial expert, susan J Demirors With over 13 years of experience, her expertise in market trends and chart analysis has been invaluable.
For anyone looking to navigate the complexities of investing, Susan is an excellent resource. You can connect with her on Email: susandemorirs@gmail.com or reach out via WhatsApp at +1 (472) 218-4301. Having an advisor like her made all different in my journey